28,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Expert panels interpreted 1497 scans. Participants were a median age of 75 y (range, 65-96 y), 51.4% were female, and 60.5% had mild cognitive impairment. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Review of the clinical cytogenetic literature provides compelling evidence for a specific relationship between imbalance of particular chromosomes or chromosomal regions and the appearance of defined patterns of phenotypic abnormalities. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The study sample was NHATS respondents who needed assistance with activities of daily living (ADL) or instrumental activities of daily living (IADL), and who did not live with a spouse (N = 512). 3 key findings →
Participants: 512 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Catatonia is a severe and potentially life-threatening but often reversible neuropsychiatric syndrome. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Sixty-eight human fibroblast cell strains were assayed for radioresistant DNA synthesis (RDS), which is defined here as the absence of a steep component of inhibition of DNA synthesis in a dose-response curve when rate of DNA synthesis is plotted against radiation doses from 0 to 20 Gy or more. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The plans are all normalized such that 50% of the PTV receives 30 Gy. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
ε4 heterozygous woman with mild cognitive impairment and CSF biomarker evidence of AD underwent treatment with intravenous lecanemab. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Stroke and dementia are leading causes of death and disability worldwide, requiring enhanced preventive strategies. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In highly segregated counties, Black older adults with elevated CVD demonstrated worse memory than those with lower CVD; in less segregated counties, memory levels did not differ by CVD. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Health disparities in dementia care are amplified among aging multilingual communities relative to their monolingual English-speaking counterparts, as social determinants of health and significant gaps in culturally responsive practice can contribute to misdiagnosis, underdiagnosis, and delays in intervention. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Advance care planning (ACP) in dementia has been defined as a communication process adapted to the person’s capacity, which includes, and is continued with family, in our European Association for Palliative Care Delphi study Delphi study with an expert panel from 33 countries. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The Healthy Brain Initiative: The Public Health Road Map for State and National Partnerships was recently updated for years 2018-2022, which includes recommendations for implementing emergency preparedness (EP) measures at the state and local levels with attention to the unique needs of people living with Alzheimer's disease and other related dementias (ADRD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
I’ll be applying soon. Claire: Maddie, what do you think will be different for you when you come to visits with us versus visits with an adult provider? 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
1 in 3 older adults die with or from dementia. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Blood-based biomarkers for Alzheimer’s disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. 4 key findings →
Design: cross-sectional Participants: 197 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We investigated whether vascular and lifestyle factors are associated with AD plasma and imaging biomarkers in midlife. 4 key findings →
Participants: 1,406 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We estimated associations of educational attainment and Alzheimer disease genetic risk with treatment initiation and incident dementia and compared GLP-1 receptor agonist initiators with initiators of non-sodium-glucose cotransporter 2 inhibitor second-line therapies, with a separate sodium-glucose cotransporter 2 inhibitor compa 4 key findings →
Design: cohort study Participants: 14,364 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
KEY POINTSO_LIThis paper demonstrates the feasibility of implementing Geriatric ED programs with targeted support for people living with or at risk for dementia across three distinct health systems in San Francisco. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Impairment in the comprehension of morphosyntactic and transitivity information does not feature in current diagnostic guidelines for primary progressive aphasia (PPA) or Alzheimers Diseases (AD), despite research reporting delayed sensitivity or insensitivity of these clinical populations to these linguistic domains. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Service members with traumatic brain injury are at approximately two- to four-fold higher risk of Alzheimers disease or related dementias than those without such an injury, with risk increasing with injury severity. 5 key findings →
Participants: 57 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONAPOE*{varepsilon}4 is the strongest genetic risk factor for Alzheimers disease (AD), yet its effect varies across ancestral populations. 1 key finding →
Participants: 2,733 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
IntroductionFrontotemporal lobar degeneration (FTLD) is a devastating disease that commonly results in early onset dementia, yet its rarity and heterogeneity limit large-scale research and clinical trials. 2 key findings →
Design: longitudinal study Participants: 567 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared with controls, adjusted odds of classification into a more impaired CDR category were higher in all tiers (OR 2.55-5.08, 95% CI 1.22-11.34). 1 key finding →
Design: longitudinal study Participants: 343 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For TabCAT tests, there were no notable floor or ceiling effects, and test scores were associated with age and education as expected. 3 key findings →
Design: cohort study Participants: 563 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 28,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,580 records, built mostly from automated pulls of Europe PMC (62.2% of the library) and OpenAlex (17.8%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.6% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →